JP5815725B2 - 創傷治癒組成物およびその使用方法 - Google Patents
創傷治癒組成物およびその使用方法 Download PDFInfo
- Publication number
- JP5815725B2 JP5815725B2 JP2013537646A JP2013537646A JP5815725B2 JP 5815725 B2 JP5815725 B2 JP 5815725B2 JP 2013537646 A JP2013537646 A JP 2013537646A JP 2013537646 A JP2013537646 A JP 2013537646A JP 5815725 B2 JP5815725 B2 JP 5815725B2
- Authority
- JP
- Japan
- Prior art keywords
- wound
- wound healing
- healing composition
- polypeptide
- hsp90α
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims description 32
- 230000029663 wound healing Effects 0.000 title claims description 29
- 238000000034 method Methods 0.000 title description 15
- 206010052428 Wound Diseases 0.000 claims description 49
- 208000027418 Wounds and injury Diseases 0.000 claims description 48
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 28
- 229920001184 polypeptide Polymers 0.000 claims description 24
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 24
- 239000006071 cream Substances 0.000 claims description 15
- 150000001875 compounds Chemical class 0.000 claims description 8
- 239000002674 ointment Substances 0.000 claims description 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 5
- 239000007864 aqueous solution Substances 0.000 claims description 3
- 239000006185 dispersion Substances 0.000 claims description 3
- 239000000499 gel Substances 0.000 claims description 3
- 239000006210 lotion Substances 0.000 claims description 3
- 239000006072 paste Substances 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- 101001078626 Homo sapiens Heat shock protein HSP 90-alpha A2 Proteins 0.000 claims 1
- 102000055164 human HSP90AA2P Human genes 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 9
- 206010072170 Skin wound Diseases 0.000 description 9
- 230000005012 migration Effects 0.000 description 8
- 238000013508 migration Methods 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- -1 F-3 compound Chemical class 0.000 description 6
- 230000001684 chronic effect Effects 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 210000003491 skin Anatomy 0.000 description 6
- 230000035876 healing Effects 0.000 description 5
- 108010081589 Becaplermin Proteins 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 239000003102 growth factor Substances 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 210000004927 skin cell Anatomy 0.000 description 4
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
- 102000009618 Transforming Growth Factors Human genes 0.000 description 3
- 108010009583 Transforming Growth Factors Proteins 0.000 description 3
- 230000003698 anagen phase Effects 0.000 description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 3
- 230000012292 cell migration Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 208000003790 Foot Ulcer Diseases 0.000 description 2
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 2
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 102100021923 Prolow-density lipoprotein receptor-related protein 1 Human genes 0.000 description 2
- 102000006747 Transforming Growth Factor alpha Human genes 0.000 description 2
- 101800004564 Transforming growth factor alpha Proteins 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 238000011580 nude mouse model Methods 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- XOIQMTLWECTKJL-HXPDMXKUSA-M sodium;(3r,4s)-4-[(2s,5r,7s,8r,9s)-2-[(2r,5s)-5-ethyl-5-[(2r,3s,5r)-5-[(2s,3s,5r,6r)-6-hydroxy-6-(hydroxymethyl)-3,5-dimethyloxan-2-yl]-3-methyloxolan-2-yl]oxolan-2-yl]-7-hydroxy-2,8-dimethyl-1,10-dioxaspiro[4.5]decan-9-yl]-3-methoxy-2-methylpentanoate Chemical compound [Na+].C([C@@](O1)(C)[C@H]2CC[C@@](O2)(CC)[C@H]2[C@H](C[C@@H](O2)[C@@H]2[C@H](C[C@@H](C)[C@](O)(CO)O2)C)C)C[C@@]21C[C@H](O)[C@@H](C)[C@@H]([C@@H](C)[C@@H](OC)C(C)C([O-])=O)O2 XOIQMTLWECTKJL-HXPDMXKUSA-M 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 108091006112 ATPases Proteins 0.000 description 1
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 1
- 102100024321 Alkaline phosphatase, placental type Human genes 0.000 description 1
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 1
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 1
- 101100016370 Danio rerio hsp90a.1 gene Proteins 0.000 description 1
- 101100285708 Dictyostelium discoideum hspD gene Proteins 0.000 description 1
- 101100125027 Dictyostelium discoideum mhsp70 gene Proteins 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- 101150031823 HSP70 gene Proteins 0.000 description 1
- 101000823116 Homo sapiens Alpha-1-antitrypsin Proteins 0.000 description 1
- 101001043564 Homo sapiens Prolow-density lipoprotein receptor-related protein 1 Proteins 0.000 description 1
- 101000766306 Homo sapiens Serotransferrin Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000005230 Leg Ulcer Diseases 0.000 description 1
- 102000012404 Orosomucoid Human genes 0.000 description 1
- 108010061952 Orosomucoid Proteins 0.000 description 1
- 208000004210 Pressure Ulcer Diseases 0.000 description 1
- 101710202113 Prolow-density lipoprotein receptor-related protein 1 Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 101100071627 Schizosaccharomyces pombe (strain 972 / ATCC 24843) swo1 gene Proteins 0.000 description 1
- 208000028990 Skin injury Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 102000043168 TGF-beta family Human genes 0.000 description 1
- 108091085018 TGF-beta family Proteins 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 230000010398 acute inflammatory response Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 238000011717 athymic nude mouse Methods 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229940112869 bone morphogenetic protein Drugs 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 101150052825 dnaK gene Proteins 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 102000051631 human SERPINA1 Human genes 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000029774 keratinocyte migration Effects 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 210000004925 microvascular endothelial cell Anatomy 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 108010031345 placental alkaline phosphatase Proteins 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 1
- 238000009790 rate-determining step (RDS) Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 229940116157 regranex Drugs 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000010421 standard material Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Description
本発明は、国立衛生研究所によって授与された契約番号GM67100とAR46538に基づく政府支援により成された。したがって、米国政府は本発明において一定の権利を有する。
発明の分野
本発明は、新規な創傷治癒組成物とその使用の分野に関する。特に、本発明は、すべての皮膚細胞の遊走を促進することで創傷治癒を早めるための、ポリペプチドの組成物と、これらの組成物の皮膚への局所的な塗布に関する。
上述の問題を解決するために、この開示では、比較的低分子のポリペプチド鎖を持つポリペプチド化合物の分類からなる創傷治癒のための組成物を特定する。一形態によれば、ポリペプチド鎖は鎖あたり5〜120のアミノ酸を持つ。任意で、組成物は、ポリペプチド合成物を運ぶために、薬剤媒体(例えば水溶液、懸濁液、分散液、膏薬、軟膏、ジェル、クリーム、ローション、スプレーまたはペースト)を含む。
実施例においては、以下の条件または方法を利用した。
Claims (7)
- EEKEDKEEEKEKEEKESEDKPEIEDVGSDEEEEKKDGDKKKKKKIKEKYIDQEEのアミノ酸配列からなるポリペプチド化合物を含む、創傷治癒組成物。
- ヒトhsp90αペプチドの236〜350番目のアミノ酸配列からなるポリペプチド化合物を含む、創傷治癒組成物。
- SDEEEEKKDGDKKKKKKIKEKYIDQEEのアミノ酸配列からなるポリペプチド化合物を含む、創傷治癒組成物。
- 前記ポリペプチド化合物を運ぶための薬剤媒体をさらに含み、
前記薬剤媒体は水溶液、懸濁液、分散液、膏薬、軟膏、ジェル、クリーム、ローション、スプレーまたはペーストからなる群から選択される一つである、請求項1〜3のいずれか1項に記載の創傷治癒組成物。 - 前記薬剤媒体中、前記ポリペプチドが約10μg/mlから約3mg/mlの濃度を有する、請求項4に記載の創傷治癒組成物。
- 前記薬剤媒体中、前記ポリペプチドが約30μg/mlから約500μg/mlの濃度を有する、請求項4に記載の創傷治癒組成物。
- 前記組成物を6時間毎〜約72時間毎に傷に塗布することを特徴とする、請求項4に記載の創傷治癒組成物。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2010/055319 WO2012060832A1 (en) | 2010-11-03 | 2010-11-03 | Skin wound healing compositions and methods of use thereof |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2013542954A JP2013542954A (ja) | 2013-11-28 |
JP2013542954A5 JP2013542954A5 (ja) | 2014-01-16 |
JP5815725B2 true JP5815725B2 (ja) | 2015-11-17 |
Family
ID=46024739
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013537646A Active JP5815725B2 (ja) | 2010-11-03 | 2010-11-03 | 創傷治癒組成物およびその使用方法 |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP2635293B1 (ja) |
JP (1) | JP5815725B2 (ja) |
CN (1) | CN103458914B (ja) |
CA (1) | CA2816818C (ja) |
DK (1) | DK2635293T3 (ja) |
WO (1) | WO2012060832A1 (ja) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8207118B2 (en) | 2009-07-17 | 2012-06-26 | University Of Southern California | Skin wound healing compositions and methods of use thereof |
KR102143557B1 (ko) * | 2013-08-09 | 2020-08-12 | 주식회사 리제론 | 인간 열 활성화 단백질 90a의 절편을 유효성분으로 포함하는 피부상태 개선용 조성물 |
US9468654B1 (en) | 2014-04-02 | 2016-10-18 | Ali Razavi | Drug delivery compositions and methods |
TW201821100A (zh) * | 2016-11-30 | 2018-06-16 | 財團法人工業技術研究院 | 促進細胞遷移及/或皮膚傷口癒合的胜肽、含其之醫藥組成物及其用途 |
CN107446018B (zh) * | 2017-08-07 | 2020-07-17 | 温州千瑞生物科技有限公司 | 促进伤口愈合的肽及其应用 |
WO2022178005A1 (en) | 2021-02-17 | 2022-08-25 | Oxion Dental, Llc | Stabilized active oxygen-generating antiseptic compositions, irrigation solutions, and articles |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5183805A (en) * | 1990-08-13 | 1993-02-02 | Board Of Regents, The University Of Texas System | Bioactive egf peptides for promotion of tissue regeneration and cancer therapy |
US6475490B1 (en) * | 1998-10-19 | 2002-11-05 | Fordham University | Compositions and methods for promoting tissue repair using heat shock proteins |
US7081240B1 (en) | 2000-06-28 | 2006-07-25 | Zimmer Orthobiologics, Inc. | Protein mixtures for wound healing |
TWI305778B (en) * | 2001-12-03 | 2009-02-01 | Nishida Teruo | Peptides of an expressing unit for igf-i minimal activity and their pharmaceutical use |
US20070098735A1 (en) * | 2005-10-29 | 2007-05-03 | Chandawarkar Rajiv Y | Methods for the Elimination of Pathogens and Other Particulate Agents |
EP1976864B1 (en) * | 2006-01-23 | 2012-09-26 | Imagene Co., Ltd. | Novel peptide and use thereof |
WO2008086358A1 (en) * | 2007-01-08 | 2008-07-17 | University Of Southern California Usc Stevens | Skin wound healing compositions and methods of use thereof |
-
2010
- 2010-11-03 CN CN201080070970.9A patent/CN103458914B/zh active Active
- 2010-11-03 DK DK10859369.0T patent/DK2635293T3/en active
- 2010-11-03 JP JP2013537646A patent/JP5815725B2/ja active Active
- 2010-11-03 WO PCT/US2010/055319 patent/WO2012060832A1/en active Application Filing
- 2010-11-03 EP EP10859369.0A patent/EP2635293B1/en active Active
- 2010-11-03 CA CA2816818A patent/CA2816818C/en active Active
Also Published As
Publication number | Publication date |
---|---|
CA2816818C (en) | 2019-01-22 |
DK2635293T3 (en) | 2018-06-14 |
CA2816818A1 (en) | 2012-05-10 |
EP2635293A4 (en) | 2014-04-02 |
JP2013542954A (ja) | 2013-11-28 |
CN103458914A (zh) | 2013-12-18 |
EP2635293A1 (en) | 2013-09-11 |
EP2635293B1 (en) | 2018-04-04 |
CN103458914B (zh) | 2015-11-25 |
WO2012060832A1 (en) | 2012-05-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Ahmed et al. | Processed eggshell membrane powder: Bioinspiration for an innovative wound healing product | |
Upton et al. | Vitronectin: growth factor complexes hold potential as a wound therapy approach | |
JP5815725B2 (ja) | 創傷治癒組成物およびその使用方法 | |
US8022037B2 (en) | Skin wound healing compositions and methods of use thereof | |
Kant et al. | Topical pluronic F-127 gel application enhances cutaneous wound healing in rats | |
US8455443B2 (en) | Methods of use of skin wound healing compositions | |
Koca Kutlu et al. | A comparison study of growth factor expression following treatment with transcutaneous electrical nerve stimulation, saline solution, Povidone‐iodine, and lavender oil in wounds healing | |
Johnson et al. | Coacervate delivery of HB‐EGF accelerates healing of type 2 diabetic wounds | |
US8110655B2 (en) | Method to promote hair growth and/or delay or treat hair loss by administering a TGF-β antagonist or inhibitor | |
Bazrafshan et al. | Activation of mitosis and angiogenesis in diabetes-impaired wound healing by processed human amniotic fluid | |
US5155038A (en) | Use of thrombospondin to promote wound healing | |
JP2018529675A (ja) | 局所エリスロポエチン製剤および前記製剤を用いて創傷治癒を改善するための方法および前記製剤の美容用途 | |
JP7026050B2 (ja) | 慢性創傷を治療するための組成物及び方法 | |
Akbari et al. | Effect of freeze drying on stability, thermo-responsive characteristics, and in vivo wound healing of erythropoietin-loaded trimethyl chitosan/glycerophosphate hydrogel | |
Zhao et al. | Sprayable NAHAO® hydrogel alleviates pain and accelerates rat oral mucositis wound healing | |
EP3288579A1 (en) | A novel skin medical and cosmetic care product | |
EP2244719B1 (en) | Wound healing peptides and methods of use thereof | |
Shashikumara et al. | Efficacy of 15% lysine cream in treating diabetic foot ulcers: a randomized interventional study | |
Li et al. | Recombinantly expressed rhFEB remodeled the skin defect of db/db mice | |
CN105561292A (zh) | 皮肤伤口愈合组合物及其使用方法 | |
Priya et al. | 136 Celosia argentea Linn. Leaf Extract Improves Wound Healing in Rat Burn Wound Model | |
Boykin et al. | 124 Venous Ulcer Healing Predicted by Urine Nitrate Assay: A Retrospective Study | |
Keswani et al. | 079 MMP 9 Mediates Angiopoietin‐1 Recruitment of Endothelial Progenitor Cells to Diabetic Wounds | |
Lin et al. | 094 Fibroblast Transmigration from Collagen into Fibrin/Fibronectin Gels requires Syndecan‐4 Proteoglycan | |
Gold et al. | 145 Biological Effects of Calreticulin on Wound Repair |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130924 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20131031 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20131031 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20141007 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20141226 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150128 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150316 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150811 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150812 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150901 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150924 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5815725 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |